Back to Results
First PageMeta Content
Clinical research / Pharmaceutical industry / Food and Drug Administration / Astex / Eisai / Decitabine / Hypomethylating agent / Clinical trial / Drug discovery / Pharmaceutical sciences / Pharmacology / Medicine


July 8, 2013 Astex Pharmaceuticals Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator Investigational New Drug (IND) Application and Data Presentations Planned for the Fourth Quarter DUBLIN,
Add to Reading List

Open Document

File Size: 13,47 KB

Share Result on Facebook

City

DUBLIN / /

Company

Eisai Inc. / Astex Pharmaceuticals Inc. / Astex Pharmaceuticals Astex Pharmaceuticals / Astex Pharmaceuticals / /

Event

FDA Phase / /

IndustryTerm

fixed dose oral combination product / fixed dose oral product / pharmaceutical / /

Organization

Food and Drug Administration / /

Person

James S.J. Manuso / /

Position

chief executive officer and chairman / /

Product

DACOGEN / SGI-110 / ASTX727 / Class Oral / /

ProvinceOrState

California / /

URL

http /

SocialTag